文献速递眼底病与葡萄膜炎

预测全国封锁对新血管性年龄相关性黄斑变性及视力损害的即时影响

Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report.
PubMed 文献 · Br J Ophthalmol · 2021-09-13

该回顾性队列研究利用英国INSIGHT健康数据平台2229例患者数据,预测封锁期间需启动抗VEGF治疗的新发nAMD患者数量,并基于CATT试验假对照组数据模拟未治疗12个月的视力变化。结果显示,MEH预测325例、UHB预测51例需启动治疗;未治疗12个月后,MEH维持≥70 ETDRS字母的眼比例从25.5%降至5.8%,视力<25字母的眼比例从4.3%升至14.2%。结论提示治疗延迟对视力有显著负面影响。

要点

  • 封锁期间预测MEH需启动抗VEGF的新发nAMD患者325例,UHB 51例。
  • 未治疗12个月,MEH维持≥70 ETDRS字母的眼比例从25.5%降至5.8%。
  • 未治疗12个月,MEH视力<25 ETDRS字母的眼比例从4.3%升至14.2%。

核心结论

  • 全国封锁导致nAMD治疗延迟,预测未治疗12个月后视力显著下降。
  • 结合国家健康数据平台与历史临床试验数据可增强nAMD预测建模。
  • prolonged treatment delay对视力有不利影响,应促使医疗服务提供者支持患者安全就医。

研究设计与样本

  • 回顾性队列研究,纳入INSIGHT健康数据研究数字中心的2229例英国患者去标识化数据。
  • 预测2020年3月16日至7月31日封锁期间MEH和UHB需启动抗VEGF治疗的新发nAMD患者数。
  • 基于CATT试验假对照组(n=238)数据事后分析,预测未接受抗VEGF治疗的best-measured VA变化。

主要发现

  • 封锁期间预测376例患者需启动抗VEGF治疗(MEH 325例,UHB 51例)。
  • 未治疗12个月,MEH队列维持≥70 ETDRS字母(Snellen等效6/12)的眼比例从25.5%降至5.8%;UHB从9.8%降至7.8%。
  • 未治疗12个月,MEH队列视力<25 ETDRS字母(6/96)的眼比例从4.3%升至14.2%;UHB从5.9%升至7.8%。

临床怎么用

  • 应重视nAMD患者治疗延迟的风险,鼓励在安全环境下及时接受抗VEGF治疗。
  • 可利用国家数字健康数据与历史试验数据预测服务中断对视力结局的影响。

局限性

  • 预测基于CATT试验假对照组数据,可能不完全代表真实世界人群。
  • 研究为回顾性设计,预测模型需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Predicting the impact of neovascular age-related macular degeneration (nAMD) service disruption on visual outcomes following national lockdown in the UK to contain SARS-CoV-2. METHODS AND ANALYSIS: This retrospective cohort study includes deidentified data from 2229 UK patients from the INSIGHT Health Data Research digital hub. We forecasted the number of treatment-naïve nAMD patients requiring anti-vascular endothelial growth factor (anti-VEGF) initiation during UK lockdown (16 March 2020 through 31 July 2020) at Moorfields Eye Hospital (MEH) and University Hospitals Birmingham (UHB). Best-measured visual acuity (VA) changes without anti-VEGF therapy were predicted using post hoc analysis of Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD trial sham-control arm data (n=238). RESULTS: At our centres, 376 patients were predicted to require anti-VEGF initiation during lockdown (MEH: 325; UHB: 51). Without treatment, mean VA was projected to decline after 12 months. The proportion of eyes in the MEH cohort predicted to maintain the key positive visual outcome of ≥70 ETDRS letters (Snellen equivalent 6/12) fell from 25.5% at baseline to 5.8% at 12 months (UHB: 9.8%-7.8%). Similarly, eyes with VA <25 ETDRS letters (6/96) were predicted to increase from 4.3% to 14.2% at MEH (UHB: 5.9%-7.8%) after 12 months without treatment. CONCLUSIONS: Here, we demonstrate how combining data from a recently founded national digital health data repository with historical industry-funded clinical trial data can enhance predictive modelling in nAMD. The demonstrated detrimental effects of prolonged treatment delay should incentivise healthcare providers to support nAMD patients accessing care in safe environments. TRIAL REGISTRATION NUMBER: NCT00056836.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Mollan SP, Fu DJ, Chuo CY, et al. Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report. Br J Ophthalmol. 2021. PMID: 34518162. doi:10.1136/bjophthalmol-2021-319383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。